CSL reorganisation
December 5, 2012
CSL Limited’s plasma product
operations in Australia will soon
take on the name of CSL Behring
(the company’s global plasma
business), whilst its vaccine,
pharmaceutical and diagnostics
business will operate under the
newly created name of bioCSL.
According to CSL, the name
changes are the result of a
reorganisation of CSL Biotherapies,
and the new operating
arrangements will take effect from
01 January 2013.
“The integration of CSL’s Australian
plasma product operations with CSL
Behring will create a single, globallyintegrated
supply chain for the
Company’s world-class portfolio of
plasma therapies and its promising
new recombinant products,” the
company said in a statement.
“In parallel, the establishment of
stand-alone business within the CSL
Group to focus on vaccines,
pharmaceuticals and diagnostics,
including third party logistics, will
provide a dedicated management
structure for these distinct products
and services,” the company added.
The reorganisation, will see CSL
Behring in Australia led by Dr Simon
Green.
Dr Green is a biochemist, who has
held a number of positions since
joining CSL in 1998, most recently
as Senior Vice President, Global
R&D Product Development.
Meanwhile bioCSL will be led by
Dr John Anderson, who was
formerly Vice President Commercial
Operations of CSL Biotherapies and
brings to the role more than 25
years of experience in the
pharmaceutical industry.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Dec 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Dec 12
